+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

HER2 Antibodies: Global Strategic Business Report

  • PDF Icon

    Report

  • 197 Pages
  • April 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309849
Description Jump to:

Global HER2 Antibodies Market to Reach $28.2 Billion by 2030

The global market for HER2 Antibodies estimated at US$16 Billion in the year 2022, is projected to reach a revised size of US$28.2 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2022-2030. Trastuzumab, one of the segments analyzed in the report, is projected to record 7.7% CAGR and reach US$18.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Lapatinib segment is readjusted to a revised 7.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $4.7 Billion, While China is Forecast to Grow at 6.7% CAGR

The HER2 Antibodies market in the U.S. is estimated at US$4.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 6.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 6.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Select Competitors (Total 47 Featured) -

  • Abnova Corporation
  • Biocon Ltd.
  • Bio-Techne Coporation
  • Celltrion, Inc.
  • Genentech, Inc.
  • Invivogen
  • Novartis AG
  • Pfizer, Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and the publisher's Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • HER2 Antibodies - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for HER2 Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for HER2 Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for HER2 Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Trastuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Trastuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Trastuzumab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Lapatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Lapatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Lapatinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Ado-trastuzumab emtansine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Ado-trastuzumab emtansine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Ado-trastuzumab emtansine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Pertuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Pertuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Pertuzumab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Everolimus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Everolimus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 18: World 16-Year Perspective for Everolimus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 19: World HER2 Antibodies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 21: USA Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: USA 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 24: Canada Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: Canada 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • JAPAN
  • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 26: Japan Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: Japan Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: Japan 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • CHINA
  • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 29: China Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: China Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: China 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • EUROPE
  • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 32: Europe Recent Past, Current & Future Analysis for HER2 Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 33: Europe Historic Review for HER2 Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: Europe 16-Year Perspective for HER2 Antibodies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 35: Europe Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Europe Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Europe 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • FRANCE
  • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 38: France Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: France Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: France 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • GERMANY
  • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 41: Germany Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Germany Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Germany 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • ITALY
  • Table 44: Italy Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Italy Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Italy 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 47: UK Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: UK Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: UK 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 50: Rest of Europe Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Rest of Europe Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: Rest of Europe 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 53: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: Asia-Pacific Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: Asia-Pacific 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
  • REST OF WORLD
  • Table 56: Rest of World Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: Rest of World Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: Rest of World 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abnova Corporation
  • Biocon Ltd.
  • Bio-Techne Coporation
  • Celltrion, Inc.
  • Genentech, Inc.
  • Invivogen
  • Novartis AG
  • Pfizer, Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedApril 2024
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 16 Billion
Forecasted Market Value ( USD ) by 2030 $ 28.2 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal

Related Topics

Related Reports

Global HER2 Antibodies Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global HER2 Antibodies Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 178 Pages
  • Global
From
Conjugated Monoclonal Antibodies Global Market Report 2024 - Product Image

Conjugated Monoclonal Antibodies Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Global Cancer Monoclonal Antibodies Market Report by Antibody Type, Medication Type, Application, End-User, and Region 2024-2032 - Product Image

Global Cancer Monoclonal Antibodies Market Report by Antibody Type, Medication Type, Application, End-User, and Region 2024-2032

  • Report
  • 136 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Global Market Report 2024 - Product Image

Biosimilar Monoclonal Antibodies Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030 - Product Image

Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030

  • Report
  • 185 Pages
  • Global
From

About the HER2 Antibodies Market

The HER2 (human epidermal growth factor receptor 2) antibodies market represents a specialized segment within the broader immune disorders drugs sector. These antibodies are primarily used in the treatment of certain types of cancer, most notably HER2-positive breast cancers, in which the HER2 protein is overexpressed, leading to cancer growth and spread. While the traditional focus of HER2 antibodies has been in oncology, their role in immune disorders is an emerging area of interest. Researchers are investigating the potential for HER2-targeting antibodies to modulate immune responses, which could be applicable in treating autoimmune conditions or other immune-related disorders. The development of such therapeutic agents often involves monoclonal antibodies engineered to recognize and bind specifically to the HER2 protein. Within this market, there are distinct companies with a presence, each contributing to advancements in therapy and research. Genentech, a member of the Roche Group, is a well-known player due to its development of pioneering HER2-targeted therapies. Another key player is GlaxoSmithKline, which also offers treatments in this domain. AstraZeneca and Daiichi Sankyo have collaborated to produce novel HER2-targeting therapies. Additionally, Puma Biotechnology focuses on the development of drugs for the treatment of HER2-positive breast cancer. These companies, among others, contribute to the dynamic landscape of the HER2 antibodies market within the realm of immune disorders drugs. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.